GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verastem Inc (NAS:VSTM) » Definitions » Cyclically Adjusted PS Ratio

VSTM (Verastem) Cyclically Adjusted PS Ratio : (As of May. 12, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Verastem Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Verastem Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Verastem's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verastem Cyclically Adjusted PS Ratio Chart

Verastem Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.97 5.64 - - -

Verastem Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.67 - -

Competitive Comparison of Verastem's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Verastem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Verastem's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Verastem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Verastem's Cyclically Adjusted PS Ratio falls into.


;
;

Verastem Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Verastem's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Verastem's adjusted Revenue per Share data for the three months ended in Dec. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0/133.1571*133.1571
=0.000

Current CPI (Dec. 2024) = 133.1571.

Verastem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 1.959 106.317 2.454
201809 2.527 106.507 3.159
201812 0.159 105.998 0.200
201903 0.272 107.251 0.338
201906 0.509 108.070 0.627
201909 1.460 108.329 1.795
201912 0.568 108.420 0.698
202003 0.561 108.902 0.686
202006 0.312 108.767 0.382
202009 5.559 109.815 6.741
202012 0.036 109.897 0.044
202103 0.070 111.754 0.083
202106 0.035 114.631 0.041
202109 0.000 115.734 0.000
202112 0.038 117.630 0.043
202203 0.167 121.301 0.183
202206 0.000 125.017 0.000
202209 0.000 125.227 0.000
202212 0.000 125.222 0.000
202303 0.000 127.348 0.000
202306 0.000 128.729 0.000
202309 0.000 129.860 0.000
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000
202406 0.372 132.554 0.374
202409 0.000 133.029 0.000
202412 0.000 133.157 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Verastem  (NAS:VSTM) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Verastem Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Verastem's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Verastem Business Description

Industry
Traded in Other Exchanges
Address
117 Kendrick Street, Suite 500, Needham, MA, USA, 02494
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
Executives
Daniel Calkins officer: Vice President of Finance C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Dan Paterson officer: Chief Operating Officer 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Karin Anna Tollefson director C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
Anil Kapur director 275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Bvf I Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc other: See Explanation of Responses 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd. other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp other: See Explanation of Responses P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert 10 percent owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104